453 related articles for article (PubMed ID: 11342772)
1. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
2. Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases.
Soomro IN; Oliveira R; Ronan J; Chaudry ZR; Johnson J
J Pak Med Assoc; 2005 May; 55(5):205-9. PubMed ID: 15960287
[TBL] [Abstract][Full Text] [Related]
3. Patterns of keratin polypeptides in 110 biphasic, monophasic, and poorly differentiated synovial sarcomas.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Virchows Arch; 2000 Sep; 437(3):275-83. PubMed ID: 11037348
[TBL] [Abstract][Full Text] [Related]
4. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
[TBL] [Abstract][Full Text] [Related]
7. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
Hinterberger M; Reineke T; Storz M; Weder W; Vogt P; Moch H
Mod Pathol; 2007 Feb; 20(2):248-55. PubMed ID: 17361207
[TBL] [Abstract][Full Text] [Related]
8. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
9. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
10. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
11. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
13. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
14. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
16. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
[TBL] [Abstract][Full Text] [Related]
18. Calretinin: a novel immunocytochemical marker for mesothelioma.
Doglioni C; Dei Tos AP; Laurino L; Iuzzolino P; Chiarelli C; Celio MR; Viale G
Am J Surg Pathol; 1996 Sep; 20(9):1037-46. PubMed ID: 8764740
[TBL] [Abstract][Full Text] [Related]
19. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
20. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases.
Pelmus M; Guillou L; Hostein I; Sierankowski G; Lussan C; Coindre JM
Am J Surg Pathol; 2002 Nov; 26(11):1434-40. PubMed ID: 12409719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]